secwatch.observer — SEC 8-K summary
======================================

Issuer:     biote Corp. (BTMD)
CIK:        0001819253
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001193125-23-209103
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biote Q2 revenue up 19% to $49.3M; FY2023 guidance narrowed to lower end
------------------------------------------------------------------------

- Revenue $49.3M (+19.1% YoY) driven by procedure (+9.8%) and supplement (+52.8%) growth; gross margin 67.9% (+60 bps).
- GAAP net loss $(13.1M) ($(0.25)/share) vs $(21.3M) ($(0.34)) prior year; adjusted EBITDA $14.5M (+10.6%).
- FY2023 guidance lowered to lower end of range: revenue $190-200M, adjusted EBITDA $56-60M, citing moderate H2 pace.
- Completed warrant exchange and secondary offering to enhance share liquidity; launched Men's Health division and trials for expanded wellness products.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819253/000119312523209103/0001193125-23-209103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819253/000119312523209103/d516871d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-209103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer